Columvi and Guidance on Intravenous Administration

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

This article responds to your request for information on Columvi® (glofitamab) and instructions for administration.

Download article Download

Last updated January 06, 2024

Guidance on the administration of Columvi

Prior to administration

Columvi must be administered as an intravenous infusion through a dedicated infusion line as per your local label.

Use of in-line filter is optional according to your local label.

Roche does not have any recommendation regarding a prime or flush with the drug product prior to administration of Columvi infusion bag. However, depending upon your local procedure the infusion set and inline filter may be primed with diluted Columvi solution prior to infusion.[1,2]

Adapt the dose, infusion volume, infusion time and infusion rate according to the treatment day and cycle and if required to the individual clinical situation of the patient.

During admiinstration

Administer the diluted Columvi infusion solution at a constant rate until the Columvi infusion bag is empty. For example, for administering Columvi 2.5 mg dose (25 mL) on Cycle 1 Day 8 with a total infusion time of four hours, administer Columvi at the rate of 6.25 mL/hour until the infusion bag is empty.

Once the Columvi infusion bag is empty, replace the Columvi infusion bag with a 0.9% sodium chloride bag on the same dedicated line. Note that the dedicated infusion line will still contain Columvi solution.[1,2]

Continue the Columvi infusion at 6.25 mL/hour until the Columvi dose solution is completely administered, which is when the total infusion time of 4 hours is reached.[2]

After administration

At the completion of the Columvi infusion, it is recommended to flush the line with 0.9% sodium chloride solution as per your local procedure.[1,2]

References

  1. Roche Internal Technical Report (Accessed on 10 Dec 2023).
    1. Roche Internal Technical Report (Accessed on 10 Dec 2023).

      Welcome to Medically

      The Roche Science Hub

      This website is a non-promotional global resource intended to facilitate transparent scientific exchange regarding developments in medical research, diagnostics, and disease management. It is intended for healthcare professionals.

      Not a healthcare professional? Browse:

      This global website is intended for healthcare professionals outside the UK, US, Canada and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same.

      You are Leaving Medically

      By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.